Targeting the METTL5–MGST1 axis for cancer therapy: molecular mechanisms and therapeutic implications

The role and clinical impact of aberrant m6A RNA modification in cancer

This review systematically dissects how dysregulated m6A methylation fuels malignant transformation and progression by reinforcing core oncogenic hallmarks, sustained proliferation, metastasis, metabolic rewiring, and resistance to programmed cell death.

Lysine specific demethylase 5B promises to be a new focus of cancer drug-resistance: combination therapy.

RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting

It is argued that while epitranscriptomics represents a compelling regulatory axis in cancer cell death, advancing the field will require integrative, high-resolution, and functionally precise approaches to move beyond correlative frameworks toward mechanistic and clinically actionable insights.

Programmable ZBTB7A RNA N6-methyladenosine site-specific demethylation suppresses colorectal cancer liver metastasis

Colorectal cancer liver metastasis (CRLM) is the primary cause of CRC-related mortality, with inevitable chemoresistance to targeted therapies and immunotherapy. N6-methyladenosine (m6A), as a crucial epigenetic regulator of gene expression and cellular physiology, involved in the pathogenesis of CRLM. Precise manipula...

TRDMT1 Slows Lung Cancer Growth by Stabilizing TFRC mRNA and Triggering Ferroptosis Cell Death.

A novel TRDMT1-TFRC regulatory axis that suppresses LUAD progression through the modulation of ferroptosis is unveiled, highlighting this pathway as a promising therapeutic target for future interventions.

m6A RNA methylation in breast cancer: from epitranscriptomic regulation to therapeutic targeting.

This review systematically summarize the functional roles of m6A regulators, including writers, erasers, and readers, in breast cancer biology and highlights the emerging clinical potential of m6A regulators as diagnostic and prognostic biomarkers, as well as therapeutic targets for overcoming drug resistance.